ICCC vs ELAN

For growth investors, ImmuCell Corporation (ICCC) is the stronger pick with 51.

6% revenue growth year-over-year, versus 6. 2% for Elanco Animal Health Incorporated (ELAN). Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ImmuCell Corporation (ICCC) delivered a total return of -15.

3%, compared to -27. 0% for Elanco Animal Health Incorporated (ELAN). Over 10 years, the gap is even starker: ICCC returned +16. 2% versus ELAN's -34. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ImmuCell Corporation (ICCC) is the lower-risk stock at 0.

38β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 289% more volatile than ICCC relative to the S&P 500. On balance sheet safety, ImmuCell Corporation (ICCC) carries a lower debt/equity ratio of 55% versus 61% for Elanco Animal Health Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmuCell Corporation (ICCC) is pulling ahead at 51.

6% versus 6. 2% for Elanco Animal Health Incorporated (ELAN). On earnings-per-share growth, the picture is similar: ImmuCell Corporation grew EPS 65. 3% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, ICCC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elanco Animal Health Incorporated (ELAN) is the more profitable company, earning -4.

9% net margin versus -8. 1% for ImmuCell Corporation — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELAN leads at 5. 3% versus -6. 2% for ICCC. At the gross margin level — before operating expenses — ELAN leads at 43. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ImmuCell Corporation (ICCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

38)). Both have compounded well over 10 years (ICCC: +16. 2%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCC is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.